<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389688</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08051</org_study_id>
    <secondary_id>EORTC-08051</secondary_id>
    <secondary_id>2005-003822-25</secondary_id>
    <nct_id>NCT00389688</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery</brief_title>
  <official_title>Randomized Phase II Study of Pemetrexed and Cisplatin as Either Induction or Adjuvant Chemotherapy in Stage IB-II Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) before surgery may&#xD;
      make the tumor smaller and reduce the amount of normal tissue that needs to be removed.&#xD;
      Giving combination chemotherapy after surgery may kill any tumor cells that remain after&#xD;
      surgery. It is not yet known whether combination chemotherapy is more effective before or&#xD;
      after surgery in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of pemetrexed disodium&#xD;
      and cisplatin and comparing how well they work when given before or after surgery in treating&#xD;
      patients with stage IB or stage II non-small cell lung cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the tolerability (in terms of drug delivery and toxicity) of neoadjuvant vs&#xD;
           adjuvant chemotherapy comprising cisplatin and pemetrexed disodium in patients with&#xD;
           resectable stage IB or II non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the overall clinical response rate, pathologic complete response, and&#xD;
           resectability rate in patients treated with neoadjuvant chemotherapy.&#xD;
&#xD;
        -  Determine the surgical morbidity and mortality of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the fraction of patients in the adjuvant arm that receives chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to institution, histological subtype (squamous vs nonsquamous) and clinical stage&#xD;
      (IB vs II). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (neoadjuvant chemotherapy): Patients receive cisplatin IV over 3-6 hours and&#xD;
           pemetrexed disodium IV on day 1. Treatment repeats every 21 days for up to 3 courses in&#xD;
           the absence of disease progression or unacceptable toxicity. Four to six weeks after&#xD;
           completion of chemotherapy, patients undergo surgery.&#xD;
&#xD;
        -  Arm II (adjuvant chemotherapy): Patients undergo surgery. Beginning 4-8 weeks after&#xD;
           surgery, patients receive cisplatin and pemetrexed disodium as in arm I.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 132 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful treatment delivery</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity (no grade 4) during chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity (all grades)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall clinical response rate (neoadjuvant chemotherapy arm)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (neoadjuvant chemotherapy arm)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resectability rate (neoadjuvant chemotherapy arm)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity and mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of patients that actually receives chemotherapy (adjuvant chemotherapy arm)</measure>
  </secondary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Pathologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IB or II disease&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
          -  No mediastinal involvement by mediastinoscopy and/or positron emission tomography with&#xD;
             fludeoxyglucose F 18 scan&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3.0 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignant disease, except for the following:&#xD;
&#xD;
               -  Basocellular carcinoma of the skin&#xD;
&#xD;
               -  Adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
               -  Low-grade prostate cancer&#xD;
&#xD;
               -  Other cancer for which the patient has been disease-free for ≥ 5 years&#xD;
&#xD;
          -  No congestive heart failure or angina pectoris unless medically controlled&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled hypertension or arrhythmia&#xD;
&#xD;
          -  No active uncontrolled infection requiring antibiotics&#xD;
&#xD;
          -  No illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No pre-existing motor or sensory neurotoxicity ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior surgery for NSCLC&#xD;
&#xD;
          -  No prior or other concurrent chemotherapy for NSCLC&#xD;
&#xD;
          -  No prior or concurrent radiotherapy for NSCLC&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent targeted agents&#xD;
&#xD;
          -  No concurrent hormonal cancer therapy&#xD;
&#xD;
          -  No concurrent routine colony-stimulating factor (e.g., prophylactic filgrastim&#xD;
             [G-CSF])&#xD;
&#xD;
          -  No aspirin or nonsteroidal anti-inflammatory drugs within 5 days before or after&#xD;
             chemotherapy&#xD;
&#xD;
          -  No other concurrent experimental treatments&#xD;
&#xD;
          -  No other concurrent anticancer treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Germonpre, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

